Evaluation of the effectiveness of personalized complex therapy in patients with benign prostatic hyperplasia and chronic prostatitis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

PURPOSE OF THE STUDY: to evaluate the effectiveness of personalized complex treatment of patients with benign prostatic hyperplasia (BPH) in combination with chronic prostatitis using a combined physiotherapeutic effect, taking into account the individual chronobiological characteristics of patients.

MATERIALS AND METHODS: We examined 60 patients with benign prostatic hyperplasia and chronic prostatitis who were sent to the TUR of the prostate. Patients were divided into two groups (n = 30). The comparison group (CG) was treated with alpha-blockers and fluoroquinolones for 28 days. In the main group (MG) – personalized complex therapy. The effectiveness of treatment was evaluated at the time of treatment (visit 1), two weeks later (visit 2) and 4 weeks later (visit 3). The severity of lower urinary tract symptoms, prostate volume and residual urine volume, hemodynamic parameters in the gland were evaluated, and a bacterioscopic and bacteriological examination of prostate secretion was performed.

RESULTS: At the end of 4 weeks of therapy, statistically significant differences (p < 0.05) were found in the MG for all the studied parameters. In the bacteriological study of prostate secretions at visit 1 Escherichia coli prevailed in the crops. At visit 2 to the CG bacteria were detected in 11 (36.7%) crops, and in 10 (33.3%) patients in the MG. At visit 3, no microbial growth was detected in both groups based on the results of a bacteriological examination of prostate secretions. Initially, both groups had low hemodynamic parameters in the prostate. After the treatment, a more pronounced dynamics of improvement of blood flow in the gland by visit 2 was noted in the MG than in the GP. By visit 3, statistically significant differences were found in all the studied indicators (p < 0.05).

CONCLUSION: Thus, according to the results, a personalized comprehensive treatment of patients with benign prostatic hyperplasia and chronic prostatitis reduced the severity of lower urinary tract symptoms and manifestations of the inflammatory process in the prostate, improved hemodynamic parameters and increase of efficiency of antibacterial therapy, as evidenced by the results of bacteriological studies.

PURPOSE OF THE STUDY: to evaluate the effectiveness of personalized complex treatment of patients with benign prostatic hyperplasia (BPH) in combination with chronic prostatitis using a combined physiotherapeutic effect, taking into account the individual chronobiological characteristics of patients.

MATERIALS AND METHODS: We examined 60 patients with benign prostatic hyperplasia and chronic prostatitis who were sent to the TUR of the prostate. Patients were divided into two groups (n = 30). The comparison group (CG) was treated with alpha-blockers and fluoroquinolones for 28 days. In the main group (MG) – personalized complex therapy. The effectiveness of treatment was evaluated at the time of treatment (visit 1), two weeks later (visit 2) and 4 weeks later (visit 3). The severity of lower urinary tract symptoms, prostate volume and residual urine volume, hemodynamic parameters in the gland were evaluated, and a bacterioscopic and bacteriological examination of prostate secretion was performed.

RESULTS: At the end of 4 weeks of therapy, statistically significant differences (p < 0.05) were found in the MG for all the studied parameters. In the bacteriological study of prostate secretions at visit 1 Escherichia coli prevailed in the crops. At visit 2 to the CG bacteria were detected in 11 (36.7%) crops, and in 10 (33.3%) patients in the MG. At visit 3, no microbial growth was detected in both groups based on the results of a bacteriological examination of prostate secretions. Initially, both groups had low hemodynamic parameters in the prostate. After the treatment, a more pronounced dynamics of improvement of blood flow in the gland by visit 2 was noted in the MG than in the GP. By visit 3, statistically significant differences were found in all the studied indicators (p < 0.05).

CONCLUSION: Thus, according to the results, a personalized comprehensive treatment of patients with benign prostatic hyperplasia and chronic prostatitis reduced the severity of lower urinary tract symptoms and manifestations of the inflammatory process in the prostate, improved hemodynamic parameters and increase of efficiency of antibacterial therapy, as evidenced by the results of bacteriological studies.

About the authors

Ivan I. Barannikov

Burdenko Voronezh State Medical University

Email: vanchyck@yandex.ru

Postgraduate Student, Department of Urology

Russian Federation, 394036, Voronezh, Studentskaya str., 10

Andrey V. Kuzmenko

Burdenko Voronezh State Medical University

Author for correspondence.
Email: kuzmenkoav09@yandex.ru
SPIN-code: 6981-7490
Scopus Author ID: 7003998310
http://vrngmu.ru/academy/personnel/978/

Dr. Sci. (Med.), professor, Head of the Department of Urology

Russian Federation, 394036, Voronezh, Studentskaya str., 10

Timur А. Gyaurgiev

Burdenko Voronezh State Medical University

Email: tima001100@mail.ru
ORCID iD: 0000-0002-6261-3641
SPIN-code: 8050-7190

Cand. Sci. (Med.)

Russian Federation, 394036, Voronezh, Studentskaya str., 10

Vladimir V. Kuzmenko

Burdenko Voronezh State Medical University

Email: kuzmenkoVV2003@mail.ru

Dr. Sci. (Med.)

Russian Federation, 394036, Voronezh, Studentskaya str., 10

References

  1. Aljaev JG, Glybochko PV, Pushkar’ DJ, editors. Urologija. Rossijskie klinicheskie rekomendacii. Moscow: GEOTAR-Media, 2018. 480 p. (In Russ.)
  2. Europian association of Uroligy [Internet]. Gravas S, Cornu JN, Gacci M, et al. Management of non-neurogenic male lower urinary tract symptoms (LUTS). EAU Guideline, 2020. [updated 01.02.2021]. Available from: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.
  3. Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. Campbell- Walsh. Urology. 10th edition. 2012:2570–2610. doi: 10.1016/B978-1-4160-6911-9.00091-8
  4. Gupta N, Rogers T, Holland B, et al. Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. J Urol. 2018;200(2): 405–413. doi: 10.1016/j.juro.2018.02.3088
  5. Roehrborn CG, Barkin J, Tubaro A, et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int. 2014;113(4):623–635. doi: 10.1111/bju.12500
  6. Mustafaev AT, Kyzlasov PS, Dianov MP, et al. Surgical treatment of benign prostatic hyperplasia: the past and the present. Urologicheskie vedomosti. 2019;9(1):47–56. (In Russ.) doi: 10.17816/uroved9147-56
  7. Roehrborn CG, Oyarzabal Perez I, Roos EP, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with nitiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116(3):450–459. doi: 10.1111/bju.13033
  8. Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. Combination drug therapy in patients with BPH. Urologiia. 2018;(1):101–105. (In Russ.) doi: 10.18565/urology.2018.1.101-105
  9. Nickel J. Prostatitis. CUA Guidelines. Can Urol Assoc J. 2011;5(5):306–315. doi: 10.5489/cuaj.11211
  10. Rees J, Abrahams M, Doble A, Cooper A; Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509–525. doi: 10.1111/bju.13101
  11. Kudryavcev YuV, Sivkov AV. Morphological alteration in benign prostatic hyperplasia tissue. Experimental and Clinical Urology. 2010;(1):18–22. (In Russ.)
  12. Bartoletti R, Cai T, Mondaini N, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol. 2007;178(6):2411–2415; discussion 2415. doi: 10.1016/j.juro.2007.08.046
  13. Huang XH, Qin B, Liang YW. LUTS in BPH patients with histological prostatitis before and after transurethral resection of the prostate. Zhonghua Nan Ke Xue. 2013;19(1):35–39. (In Chinese).
  14. Krsmanovic A, Tripp D, Nickel J, et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Can Urol Assoc J. 2014;8(11–12):403–408. doi: 10.5489/cuaj.2179
  15. Asgari SA, Mohammadi M. The role of intraprostatic inflammation in the acute urinary retention. Int J Prev Med. 2011;2(1):28–31.
  16. Al-Shukri SK, Tkachuk VN, Gorbachev AG, et al. Urodinamicheskie issledovanija v diagnostike infravezikal’noj obstrukcii u muzhchin. Urologiia i nefrologiia. 1998;(6):27–29. (In Russ.)
  17. Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. Acute respiratory infections, viruses, children, recombinant interferon alfa-2b. RMJ. 2019;27(10):46–49. (In Russ.)
  18. Nesterov SN, Hanaliev BV, Boneckij BA, et al. Infekcionno-vospalitel’nye oslozhnenija transuretral’noj rezekcii predstatel’noj zhelezy u pacientov s hronicheskim prostatitom. Bulletin of the Dagestan State Medical Academy. 2017;4(25):51–54. (In Russ.)
  19. Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. The efficacy of fesoterodine in patients after transurethral resection of the prostate. Urologiia. 2019;(1):52–55. (In Russ.) doi: 10.18565/urology.2019.1.52-55
  20. Martov AG, Merinov DS, Kornienko SI, et al. Posleoperacionnye urologicheskie oslozhnenija transuretral’nyh jelektrohirurgicheskih vmeshatel’stv na predstatel’noj zheleze po povodu adenomy. Urologiia. 2006;(2):25–31. (In Russ.)
  21. Al-Shukri SK, Gorbachev AG, Borovets SY, et al. Lechenie bol’nyh adenomoj predstatel’noj zhelezy prostatilenom. Urologiia. 2006;(6):22–25. (In Russ.)
  22. Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA, Barannikov II. Chronobiological status of patients with chronic prostatitis and prostate adenoma. Sistemnyj analiz i upravlenie v biomedicinskih sistemah. 2017;16(3):513–516. (In Russ.)
  23. Lanina VA, Himicheva MN, Kuz’menko VV, et al. Hronobiologicheskie osobennosti bol’nyh s hronicheskim prostatitom pri adenome prostaty. Tendencii razvitija nauki i obrazovanija. 2020;66(1):111–114. (In Russ.)
  24. Hanina EA, Zujkova AA, Pashkov AN. Individual’nyj hronoritm v kontekste korrekcii narushenij adaptacii pri patologii vnutrennih organov. Bukovinian Medical Herald. 2009;13(24):259–260. (In Russ.)
  25. Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. Chronobiological approach to the treatment of chronic recurrent bacterial cystite. Urologiia. 2017;(2):60–65. (In Russ.) doi: 10.18565/urol.2017.2.60-65
  26. Popkov VM, Kirichuk VF, Loyko VS, et al. Experience of terahertz therapy in benign prostatic hyperplasia combined with chronic abacterial prostatitis. Saratov Journal of Medical Scientific Research. 2014;10(4):649–654. (In Russ.)
  27. Vaupel P, Kelleher DK. Blood flow and oxygenation status of prostate cancers. Adv Exp Med Biol. 2013;765:299–305. doi: 10.1007/978-1-4614-4989-8_42
  28. Savushkin MS, Belova IB. The transrectal dopplerography in diagnostics of diseases of a prostate. Bulletin of Pirogov National Medical and Surgical Center. 2013;8(2):83–86. (In Russ.)
  29. Krupin VN, Krupin AV, Nashivochnikova NA. Evaluation of blood flow in prostate in patients with chronic bacterial prostatitis. Urologicheskie vedomosti. 2017;7(3):38–43. (In Russ.) doi: 10.17816/uroved7338-43
  30. Al-Shukri SK, Gorbachev AG, Borovets SY. Pathogenesis and prophylaxis of chronic prostatitis (clinical and experimental study). Urologicheskie vedomosti. 2012;2(2):15–19. (In Russ.) doi: 10.17816/uroved2215-19
  31. El Basri A, Petrolekas A, Cariou G, et al. Clinical significance of routine urinary bacterial culture after transurethral surgery: results of a prospective multicenter study. Urology. 2012;79(3):564–569. doi: 10.1016/j.urology.2011.11.018
  32. Choong S, Whitfield H. Biofilms and their role in infections in urology. BJU Int. 2000;86(8):935–941. doi: 10.1046/j.1464–410x.2000.00949.x

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Patient P. (main group). Doppler TRUS of the prostate before treatment: a – urethral branches of the artery of the prostate; b – capsular branches of the prostate artery

Download (192KB)
Indexing metadata
3. Fig. 2. Patient P. (main group). Doppler TRUS of the prostate after treatment at visit 3: a – urethral branches of the prostate artery; b – сapsular branches of the prostate artery

Download (205KB)
Indexing metadata

Copyright (c) 2021 Eco-Vector


 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».